IMMUNOLOGIC COMPETENCE OF PATIENTS WITH PSORIASIS RECEIVING CYTOTOXIC DRUG THERAPY.
D000485:Allergens; D000486:Allergy and Immunology; D000814:Aniline Compounds; D000917:Antibody Formation; D000937:Antigen-Antibody Reactions; D000970:Antineoplastic Agents; D001379:Azathioprine; D001554:Benzene; D002396:Catechols; D005853:Geriatrics; D006801:Humans; D006968:Hypersensitivity, Delayed; D007121:Immunocompetence; D007166:Immunosuppressive Agents; D015122:Mercaptopurine; D008727:Methotrexate; D010600:Pharmacology; D010931:Plague Vaccine; D011565:Psoriasis; D013866:Thioguanine; D014265:Triethylenemelamine; D014747:Vinblastine
D000485:Allergens; D000814:Aniline Compounds; D000970:Antineoplastic Agents; D002396:Catechols; D007166:Immunosuppressive Agents; D010931:Plague Vaccine; D014747:Vinblastine; D015122:Mercaptopurine; D014265:Triethylenemelamine; D013866:Thioguanine; D001554:Benzene; C034221:catechol; D001379:Azathioprine; D008727:Methotrexate
ALLERGENS; ANILINE COMPOUNDS; ANTIBODY FORMATION; ANTIGEN-ANTIBODY REACTIONS; ANTINEOPLASTIC AGENTS; AZATHIOPRINE; BENZENE; CATECHOL; GERIATRICS; HYPERSENSITIVITY, DELAYED; IMMUNOLOGY; IMMUNOSUPPRESSIVE AGENTS; MERCAPTOPURINE; METHOTREXATE; PHARMACOLOGY; PLAGUE VACCINE; PSORIASIS; THIOGUANINE; TRIETHYLENE MELAMINE; VINBLASTINE